The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed and funded by Alkermes, Inc.
Showing 10 of 99 results
Sort by date:
Descending
Aug 2025
Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia
Neuropsychiatric Disease and Treatment
AUTHOR(S)
Jul 2025
Healthcare Resource Utilization 6 Months Before and After Olanzapine/Samidorphan Initiation: Real-World Assessment of Patients with Schizophrenia or Bipolar I Disorder
Advances in Therapy
AUTHOR(S)
May 2025
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia
Advances in Therapy
AUTHOR(S)
Apr 2025
Treatment patterns and healthcare resource use among veterans initiating medication for incident moderate-to-severe alcohol use disorder
The American Journal on Addictions
AUTHOR(S)
Apr 2025
Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial
Neuropsychiatric Disease and Treatment
AUTHOR(S)
Mar 2025
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
Neuropsychiatric Disease and Treatment
AUTHOR(S)
Jan 2025
Olanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind Studies
The Journal of Clinical Psychiatry
AUTHOR(S)
Dec 2024
Opioid antagonists: clinical utility, pharmacology, safety, and tolerability
CNS Spectrums
AUTHOR(S)
Dec 2024
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Aug 2024
Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder
BMC Psychiatry
AUTHOR(S)
